Goldman Sachs raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $44 and keeps a Sell rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics’ Earnings Call Highlights Success and Challenges
- PTC Therapeutics price target raised to $82 from $70 at RBC Capital
- PTC Therapeutics price target raised to $63 from $50 at TD Cowen
- PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs
- PTC Therapeutics price target raised to $80 from $68 at JPMorgan